A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01144351 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: ELND002
DRUG: Placebo

Sponsor

Elan Pharmaceuticals